![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Gentex Corp. | TG:GTX | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.40 | -4.64% | 28.80 | 28.60 | 28.80 | 30.00 | 28.00 | 30.00 | 140 | 22:50:16 |
RNS Number:0268P Genetix Group PLC 27 August 2003 Genetix Appoints Chief Operating Officer New Milton UK, 27 August 2003 - Genetix Group plc (LSE: GTX), the genomics and proteomics technology group, today announces the appointment of Trevor Bell, 46, as Chief Operating Officer with effect from 15 September 2003. With a background in international marketing and brand management gained in a variety of blue chip consumer goods companies including Procter & Gamble and Jacobs Suchard, Mr Bell has spent much of the last 14 years operating in senior General Management positions in Europe, North America and Asia Pacific. These have included Remy Cointreau SA, where he was Managing Director Northern Europe, and in the Healthcare sector with Scholl plc, where, as Board Director responsible for Global Commercial Operations, he achieved significant sales and profit growth prior to the agreed merger of the company in June 1998 with Seton Healthcare plc. Mr Bell has extensive experience of the key North American market, which accounts for over 50% of Genetix's sales, having been resident in the United States in his most recent corporate position as President of Schwinn Fitness, the manufacturer and marketer of fitness equipment, based in Boulder, Colorado. Since leaving Schwinn, Mr Bell has been advising a number of companies in the USA, Asia Pacific and Europe. Mark Reid, CEO of Genetix, said: "We are pleased to welcome Trevor to the Board. His broad business experience and international marketing expertise will be of particular benefit to Genetix and his appointment marks a further strengthening of our executive team." With reference to paragraphs 16.4 and 6.F.2 (b)-(g). of the UKLA's Listing Rules there are no other disclosures required other than in respect of paragraph 6.F.2 (d), where after leaving the company in October 2000 Schwinn/GT UK Sales was put into administrative receivership in March 2001 as part of internal reorganisation. Enquiries: Genetix Group plc Mark Reid, Chief Executive Officer Tel: +44 (0) 1425 624600 Gary Corsi, Finance Director Financial Dynamics Jonathan Birt / Sarah MacLeod Tel: +44 (0) 7831 3113 Notes to Editors Genetix Group plc is based in New Milton, Hampshire, UK. It develops, manufactures and markets high-throughput equipment and related items used for research into human and plant genomics, proteomics and cell biology. The Company currently supplies equipment to more than 150 customers worldwide in the pharmaceutical, agricultural and food industries including GlaxoSmithKline, AstraZeneca, Novartis, Celera Genomics, Millennium Pharmaceuticals and the Max Planck Institutes. In addition, the Group has made a significant contribution to the Human Genome Project by supplying equipment to seven of the leading eight laboratories involved in the consortium. Genetix acquired the Genpak group in October 2000 before floating successfully on the London Stock Exchange in November 2000. This information is provided by RNS The company news service from the London Stock Exchange END MSCILFLSTIIRFIV
1 Year Gentex Chart |
1 Month Gentex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions